行情

AVXL

AVXL

Anavex Life
NASDAQ

实时行情|Nasdaq Last Sale

2.480
+0.080
+3.33%
休市 16:00 11/15 EST
开盘
2.450
昨收
2.400
最高
2.500
最低
2.412
成交量
25.85万
成交额
--
52周最高
4.090
52周最低
1.250
市值
1.31亿
市盈率(TTM)
-4.1472
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AVXL 新闻

  • 关厂风波肆起、显示屏遭质疑:三星能否靠5G绝地求生
  • 蓝鲸TMT.20分钟前
  • 约翰逊承诺结束令经济“陷入瘫痪”的英退不确定性
  • 新浪财经综合.30分钟前
  • 一周财经日历丨美团、拼多多财报出炉,阿里或于周三定价
  • 华盛通.35分钟前
  • 蔚来宣布奉玮出任CFO 后者曾任中金研究部董事总经理
  • 新浪科技.1小时前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

AVXL 简况

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand. As of September 30, 2016, the Company had not generated any revenues from its operations.
展开

Webull提供Anavex Life Sciences Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。